Kathleen D. Scott

Kathleen D. Scott (board member) discloses dealings in 2 companies, chiefly ARS Pharmaceuticals, Inc. and Dermata Therapeutics, Inc. Between 7 April 2022 and 16 June 2026, the trades on record add up to 9 filings.

Both buying and selling appear: 1 purchase worth €50k, against 1 sale. The totals exclude 1 filing filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 3 share grants and 4 option exercises. So far in 2026, the count stands at no purchases and 1 sale.

Most recently, on 16 June 2026, the filings show an open-market sale in Dermata Therapeutics, Inc. The latest purchase dates back some time: it was published 1,417 days ago, on 1 December 2022. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.